যুক্তরাজ্য - ইংরেজি - MHRA (Medicines & Healthcare Products Regulatory Agency)

lexon (uk) ltd - pentoxifylline - modified-release tablet - 400mg

যুক্তরাজ্য - ইংরেজি - MHRA (Medicines & Healthcare Products Regulatory Agency)

necessity supplies ltd - pentoxifylline - modified-release tablet - 400mg

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

bryant ranch prepack - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline extended-release tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. pentoxifylline can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease. pentoxifylline should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

ani pharmaceuticals, inc. - pentoxifylline (unii: sd6qct3tsu) (pentoxifylline - unii:sd6qct3tsu) - pentoxifylline extended-release tablets are indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. pentoxifylline extended-release tablets can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease. pentoxifylline extended-release tablets should not be used in patients with recent cerebral and/or retinal hemorrhage or in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.

মাল্টা - ইংরেজি - Medicines Authority

generis phar, unipessoal, lda rua joao de deus, 19 2700-487 amadora , portugal - modified-release tablet - pentoxifylline 400 mg - peripheral vasodilators

সিঙ্গাপুর - ইংরেজি - HSA (Health Sciences Authority)

duopharma (singapore) pte ltd - pentoxifylline - tablet, film coated - 400 mg - pentoxifylline 400 mg

আয়ার্লণ্ড - ইংরেজি - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited - pentoxifylline - modified-release tablets - 400 milligram

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ciprofloxacin hydrochloride, quantity: 873 mg (equivalent: ciprofloxacin, qty 750 mg) - tablet, film coated - excipient ingredients: hypromellose; titanium dioxide; croscarmellose sodium; colloidal anhydrous silica; povidone; sodium starch glycollate type a; stearic acid; macrogol 6000; microcrystalline cellulose; purified talc; magnesium stearate - ciprofloxacin sandoz is indicated for the treatment of infections caused by susceptible organisms in the following conditions: urinary tract infections, gonorrhoeal urethritis and cervicitis, gastroenteritis, bronchial infections, skin and skin structure infections, bone and joint infections, chronic bacterial prostatitis of mild to moderate severity. typhoid and paratyphoid infections and infections due to multiresistant staph. aureus are excluded from the above due to insufficient data. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the medicine of choice in cases with gram-positive infections, such as pneumonia due to strep. pneumoniae. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of n. gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin sandoz may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin sandoz is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents additional therapy should be considered.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ciprofloxacin hydrochloride, quantity: 582 mg (equivalent: ciprofloxacin, qty 500 mg) - tablet, film coated - excipient ingredients: stearic acid; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate type a; croscarmellose sodium; povidone; hypromellose; macrogol 6000; purified talc; titanium dioxide; magnesium stearate - ciprofloxacin sandoz is indicated for the treatment of infections caused by susceptible organisms in the following conditions: urinary tract infections, gonorrhoeal urethritis and cervicitis, gastroenteritis, bronchial infections, skin and skin structure infections, bone and joint infections, chronic bacterial prostatitis of mild to moderate severity. typhoid and paratyphoid injections and injections due to multiresistant staph. aureus are excluded from the above due to insufficient data. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the medicine of choice in cases with gram-positive infections, such as pneumonia due to strep. pneumoniae. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of n. gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin sandoz may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin sandoz is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents additional therapy should be considered.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ciprofloxacin hydrochloride, quantity: 291 mg (equivalent: ciprofloxacin, qty 250 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate type a; microcrystalline cellulose; stearic acid; purified talc; colloidal anhydrous silica; croscarmellose sodium; povidone; hypromellose; magnesium stearate; titanium dioxide; macrogol 6000 - ciprofloxacin sandoz is indicated for the treatment of infections caused by susceptible organisms in the following conditions: urinary tract infections, gonorrhoeal urethritis and cervicitis, gastroenteritis, bronchial infections, skin and skin structure infections, bone and joint infections, chronic bacterial prostatitis of mild to moderate severity. typhoid and paratyphoid infections and infections due to multiresistant staph. aureus are excluded from the above due to insufficient data. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the medicine of choice in cases with gram-positive infections, such as pneumonia due to strep. pneumoniae. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of n. gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin sandoz may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin sandoz is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents, additional therapy should be considered.